|
Mechanisms of Leukemogenesis in Down Syndrome |
5R01CA101774-18 |
CRISPINO, JOHN D |
NCI |
2020 |
|
Evaluation of myocardial targets to prevent anthracycline cardiotoxicity in children with Down Syndrome and Leukemia |
5R21CA245067-02 |
BLANCO, JAVIER G |
NCI |
2020 |
|
Applications of high resolution fMRI in ultra-high field (7T) in revealing developmental disorders underlying amblyopia |
1 R01 EY030434-01A1 |
NASR, SHAHIN |
NEI |
2020 |
|
Discovery of susceptibility genes for Down syndrome-associated congenital heart defects using whole genome sequencing |
1 R03 HL156476-01 |
LESLIE, ELIZABETH JANE |
NHLBI |
2020 |
|
ARIZONA PRIDE-25: TRANSLATIONAL APPROACHES TO HEALTH DISPARITIES IN THE LUNG |
5R25HL126140-06 |
GARCIA, JOE G N |
NHLBI |
2020 |
|
Erroneous Coding of Developmental Disabilities as Underlying Cause of Death |
1 R03 AG065638-01 |
LANDES, SCOTT D |
NIA |
2020 |
|
Noninvasive Low-cost Biomarkers for Preclinical Diagnosis and Longitudinal Tracking of Alzheimers Disease Using Sleep and Resting State EEG |
5R01AG054081-04 |
PURDON, PATRICK L |
NIA |
2020 |
|
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders |
5R01MH092769-11 |
BURRIS, THOMAS P |
NIA |
2020 |
|
Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease |
5R01NS099535-04 |
BOHNEN, NICOLAAS IDA |
NIA |
2020 |
|
Bronchus-Associated Lymphoid Tissue & Lung Infection in Down Syndrome |
5R21HL151256-02 |
YEAGER, MICHAEL E |
NIA |
2020 |